
235
00DH
300.00 DH
-22%
Bad Blood: Secrets and Lies in a Silicon Valley Startup
Livraison
DétailsFrais de livraison à partir de :
Livraison entre le Mardi 30 juin 2026 et le Mercredi 1 juillet 2026
À propos de cet article :
Marque : GENERIC
Vendu par KECHBOOK
NATIONAL BESTSELLER • The gripping story of Elizabeth Holmes and Theranos—one of the biggest corporate frauds in history—a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword covering her trial and sentencing, bringing the story to a close.“Chilling ... ...
Partagez ce produit
1
Mode de paiement
Paiement par carte bancaire
Carte marocainesPaiement à la livraison
Paiement en espèce à la livraison
Politique de retours
Note de politique de retour
Description produit
- Marque
- GENERIC
- Titre principal
- Bad Blood: Secrets and Lies in a Silicon Valley Startup
- Editeur
- Vintage
- Type de produit
- paperback
- Présentation du livre
- paperback
- Release date
- 1/28/2020 12:00:00 AM
- Langue d'origine
- English
- ISBN
- 525431993
- Dimensions
- 5.15 x 0.91 x 7.95 inches
- Nombre de pages de livre
- 400 pages
- Langue - Librairie
- English
- Résumé
- NATIONAL BESTSELLER • The gripping story of Elizabeth Holmes and Theranos—one of the biggest corporate frauds in history—a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword covering her trial and sentencing, bringing the story to a close.“Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection.” —The New York Times Book ReviewIn 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees. Read more
- Auteur(s)
- John Carreyrou
- Date de parution
- 1/28/2020 12:00:00 AM









